461-28-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-1-propanesulfonyl chloride is used as a reagent for the synthesis of pharmaceuticals, where it plays a crucial role in introducing the sulfonyl group into organic molecules. This contributes to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Fluoro-1-propanesulfonyl chloride is used as a key intermediate in the preparation of sulfonylurea herbicides. These herbicides are essential for effective and selective weed control in agricultural settings, promoting crop health and yield.
Used in Organic Synthesis:
3-Fluoro-1-propanesulfonyl chloride is utilized as a versatile reagent in organic synthesis, enabling the introduction of the sulfonyl group into a wide range of organic molecules. This enhances the functionalization and modification of these molecules, leading to the creation of new compounds with diverse applications in various fields.

InChI:InChI=1/C3H6ClFO2S/c4-8(6)7-3-1-2-5/h1-3H2

Upstream product

• 408-00-4 3-fluoropropyl thiocyanate 
• 1033906-64-7 (3-fluoropropyl)ethanethioate 

Downstream Products

• 461-29-0 3-fluoro-propane-1-sulfonyl fluoride 
• 1107610-29-6 1-(3-fluoropropylsulfonyl)-4-(2-methoxyphenyl)piperazine 
• 1107610-28-5 ethyl (S)-2-(3-fluoropropylsulfonamido)-3-phenylpropanoate 
• 1362739-45-4 benzyl 6-chloro-2-fluoro-3-(3-fluoropropylsulfonamido)benzoate 

Relevant academic research and scientific papers

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Use of 3-[18F]fluoropropanesulfonyl chloride as a prosthetic agent for the radiolabelling of amines: Investigation of precursor molecules, labelling conditions and enzymatic stability of the corresponding sulfonamides

3-[18F]Fluoropropanesulfonyl chloride, a recently proposed prosthetic agent for fluorine-18 labelling, was prepared in a two-step radiosynthesis via 3-[18F]fluoropropyl thiocyanate as an intermediate. Two benzenesulfonate-based radiolabelling precursors were prepared by various routes. Comparing the reactivities of 3-thiocyanatopropyl nosylate and the corresponding tosylate towards [18F]fluoride the former proved to be superior accounting for labelling yields of up to 85%. Conditions for a reliable transformation of 3-[18F]fluoropropyl thiocyanate to the corresponding sulfonyl chloride with the potential for automation have been identified. The reaction of 3-[18F]fluoropropanesulfonyl chloride with eight different aliphatic and aromatic amines was investigated and the identity of the resulting 18F-labelled sulfonamides was confirmed chromatographically by comparison with their nonradioactive counterparts. Even for weakly nucleophilic amines such as 4-nitroaniline the desired radiolabelled sulfonamides were accessible in satisfactory yields owing to systematic variation of the reaction conditions. With respect to the application of the 18F-fluoropropan-sulfonyl group to the labelling of compounds relevant as imaging agents for positron emission tomography (PET), the stability of N-(4-fluorophenyl)-3-fluoropropanesulfonamide against degradation catalysed by carboxylesterase was investigated and compared to that of the analogous fluoroacetamide.

CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS

The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV